Skip to main content
SpringerLink
Log in

The role of clinical pharmacist on lipid control in dyslipidemic patients in North of Jordan

  • Research Article
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Objective The purpose of this study is to investigate the effectiveness of introducing clinical pharmacy services in achieving goal lipid profile in dyslipidemia patients in North of Jordan. Setting the study was carried out in a primary care facility in North of Jordan. Methods: One hundred fifty two dyslipidemia patients were randomized into intervention and control groups and followed for 6 months period. Intervention group patients were followed intensively by a clinical pharmacist who worked closely with physicians in controlling lipid profiles according to the third edition of recommendations by The National Cholesterol Education Program Adult Treatment Panel, control group patients were provided with standard medical care. Main outcome measure percent of patients at their low density lipoprotein cholesterol target in the intervention group compared to percent of patients at their low density lipoprotein cholesterol target in the control group by the end of the study. Results: One hundred twenty five patients completed the study duration. After 6 months, 94.5% of intervention group patients and 71.2 % of control group patients reached their goal low density lipoprotein cholesterol levels (P value < 0.001, Pearson Chi-Square test) compared to 24.7 and 28.8% respectively at baseline. Majority of pharmacist recommendations (90.4%) were followed by physicians and overall lipid lowering agents use was increased to 91.8% in intervention group patients and 86.5% in control group patients compared to 69.9 and 78.8% respectively at baseline. Conclusion: Implementing clinical pharmacy services in Jordan has improved the lipid profiles of dyslipidemic patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Haung PL. A comprehensive definition for metabolic syndrome. Dis Model Mech. 2006;2(5–6):231–7.

    Google Scholar 

  2. Hammoudeh AJ, Izraiq M, Al-Mousa E, Al-Tarawneh H, Elharassis A, Mahadeen Z, et al. Serum lipid profiles with and without CAD: Jordan hyperlipidaemia and related targets study (JoHARTS-1). East Mediterr Health J. 2008;14(1):24–32.

    PubMed  CAS  Google Scholar 

  3. Geller JC, Cassens S, Brosz M, Keil U, Bernarding J, Kropf S, et al. Achievement of guideline-defined treatment goals in primary care: the German coronary risk management (CoRiMa) study. Eur Heart J. 2007;28:3051–8.

    Article  PubMed  CAS  Google Scholar 

  4. Bozovich M, Rubino CM, Edmunds J. Effect of a clinical pharmacist-managed lipid clinic on achieving national cholesterol education program low density lipoprotein goals. Pharmacotherapy. 2000;20(11):1375–83.

    Article  PubMed  CAS  Google Scholar 

  5. Carter BL, Malone DC, Billups SJ, Valuck RJ, Barnette DJ, Sintek CD, et al. Interpreting the findings of the IMPROVE study. Am J Health Sys Pharm. 2001;58(14):1330–7.

    CAS  Google Scholar 

  6. Yates S, Annis L, Pippins J, Walden S. Does a lipid clinic increase compliance with cholesterol education program treatment guidelines? Report of a case-matched controlled study. South Med J. 2001;94:907–9.

    PubMed  CAS  Google Scholar 

  7. Mazzolini TA, Irons BK, Schell EC, Seifert CF. Lipid levels and use of lipid-lowering drugs for patients in pharmacist-managed lipid clinics versus usual care in a 2 VA medical centers. J Manag Care Pharm. 2005;11(9):763–71.

    PubMed  Google Scholar 

  8. Till LT Jr, Voris JC, Horst JB. Assessment of clinical pharmacist management of lipid-lowering therapy in a primary care setting. J Manag Care Pharm. 2003;9(3):269–73.

    PubMed  Google Scholar 

  9. Lee VWY, Fan CSY, Li AWM, Chau ACY. Clinical impact of a pharmacist co-managed programme on hyperlipidaemia management in Hong Kong. J Clinic Pharm Therap. 2009;34:407–14.

    Article  CAS  Google Scholar 

  10. Phumipamorn S, Pongwecharak J, Soorapan S, Pattharachayakul S. Effects of the pharmacist’s input on glycaemic control and cardiovascular risks in Muslims diabetes. Prim Care Diabetes. 2008;2(1):31–7. Abstract.

    Article  PubMed  Google Scholar 

  11. Al-Wazaify M, Albsoul-Younes A. Pharmacy in Jordan. Am J of Health Sys Pharm. 2005;62(23):2548–51.

    Article  Google Scholar 

  12. McDonough RP, Doucette WR. Developing collaborative working relationships between pharmacists and physicians. J Am Pharm Assoc. 2001;41(5):682–92.

    Google Scholar 

  13. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486–97.

    Article  Google Scholar 

  14. Tahaineh LM, Wazaify M, Albsoul-Younes A, Khader Y, Zaidan M. Perceptions, experiences, and expectations of physicians in hospital settings in Jordan regarding the role of the pharmacist. Res Social Adm Pharm. 2009;5(1):63–70.

    PubMed  Google Scholar 

  15. Ali F, Laurin M-Y, Lariviere C, Tremblay D, Cloutier D. The effect of pharmacist intervention and patient education on lipid-lowering medication compliance and plasma cholesterol levels. Can J Clin Pharmacol. 2003;10:101–6.

    PubMed  Google Scholar 

  16. Bogden PE, Koontz LM, Williamson P, Abbott RD. The physician and pharmacist team. An effective approach to cholesterol reduction. J Gen Intern Med. 1997;12:158–64.

    CAS  Google Scholar 

  17. Chiu CC, Wu SS, Lee PY, Huang YC, Tan TY, Chang KC. Control of modifiable risk factors in ischemic stroke outpatients by pharmacist intervention: an equal allocation stratified randomized study. J Clinic Pharm Therap. 2008;33:529–35.

    Article  Google Scholar 

  18. Davidson MH, Ose L, Frohlich J, Scott RS, Dujovne CA, Escobar ID, et al. Differential effects of simvastatin and atorvastatin on high density lipoprotein cholesterol and apolipoprotein A-1 are consistent across hypercholesterolemic patient subgroups. Clin Cardiol. 2003;26:509–14.

    Article  PubMed  Google Scholar 

  19. Bevilacqua M, Guazzini B, Righini V, Barella M, Toscano R, Chebat E. Metabolic effects of fluvastatin extended release 80 mg and atorvastatin 20 mg in patients with type 2 diabetes mellitus and low serum high-density lipoprotein cholesterol levels: a 4-month, prospective, open label, randomized, blinded-end point (Probe) trial. Curr Ther Res. 2004;65(4):330–44.

    Article  CAS  Google Scholar 

Download references

Acknowledgment

The authors would like to acknowledge all members of the Health Center of Jordan University of Science and Technology in Irbid for their assistance and cooperation. We also would like to thank Neda Radwan, RPh for her help in statistical analysis.

Funding

This work was supported by a grant from the Deanship of Research, Jordan University of Science and Technology, Irbid, Jordan.

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science & Technology (JUST), Irbid, Jordan

    Linda Tahaineh & Ala Habeb

  2. Department of Biopharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, The University of Jordan (JU), Amman, Jordan

    Abla Albsoul-Younes

  3. Department of Community Medicine, Public Health and Family Medicine, Faculty of Medicine, Jordan University of Science & Technology (JUST), Irbid, Jordan

    Eman Al-Ashqar

Authors
  1. Linda Tahaineh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abla Albsoul-Younes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eman Al-Ashqar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ala Habeb
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Linda Tahaineh.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tahaineh, L., Albsoul-Younes, A., Al-Ashqar, E. et al. The role of clinical pharmacist on lipid control in dyslipidemic patients in North of Jordan. Int J Clin Pharm 33, 229–236 (2011). https://doi.org/10.1007/s11096-011-9479-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-011-9479-0

Keywords

Search

Navigation